BioAtla Signs $40M Yorkville Equity Line, Replacing $15M SEPA
BCAB sits 22% above its 52-week low of $1.07.
Summary
BioAtla replaced its $15M Yorkville standby equity line with a $40M one, giving a cash-starved, delisted biotech a variable-price funding source at 97% of the lowest three-day VWAP — deeply dilutive if drawn, but nothing has been sold yet.
Key Events · Financing and Capital Events · BCAB
-
$40M Yorkville Standby Equity Line
BioAtla can sell up to $40.0 million of common stock to YA II PN, Ltd. over 36 months at its option; no shares have been sold under the new agreement.
-
Variable Pricing at 97% of Low VWAP
Each advance is priced at 97% of the lowest daily VWAP over the three trading days after notice, capped at 100% of average daily volume, with a company-set minimum price floor.
-
$500K Commitment Fee, Half in Warrants
The $500,000 fee equals about 2% of the $25 million increase over the prior facility; 182,110 warrants at a $0.0001 strike were issued October 16 for the first half, with the balance due by December 31, 2026.
-
Prior $15M SEPA Terminated
The November 20, 2025 Yorkville facility was terminated; only 48,092 shares were ever sold under it for roughly $0.4 million gross.
Analysis · BCAB · Life Sciences
BioAtla has no real cash cushion — the last 10-Q disclosed a going concern warning with just $1.5 million on hand and a paused Phase 1 trial — and it was delisted from Nasdaq to the OTCQB in late August. This $40 million standby equity line from Yorkville is the company's funding lifeline, but it is a variable-price facility: shares are sold at 97% of the lowest VWAP over a three-day pricing window, so the company sells into weakness and the share count can climb sharply with every draw. Against 1,668,261 shares currently outstanding, the full $40 million commitment at today's $1.31 price would imply roughly 30.5 million shares (about $40M / $1.31), a multiple of the existing base — though nothing has been drawn and the company is under no obligation to sell. The $500,000 commitment fee (about 2% of the $25 million increase over the prior facility) is real cost, half already paid in 182,110 warrants struck at $0.0001. No advance can occur until a resale registration statement is effective, and the concurrent S-1 filing is that registration step.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 37.4% of the 952 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BCAB was trading at $1.31 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $1.07 to $3,575.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.